Exhibitors

Virtual Brain Technology (Free On-Site Trials Available )Virtual Brain is the only product in Hong Kong that utilizes eye-tracking technology to accurately screen for the risk of brain degeneration and incorporates virtual reality technology for targeted brain degeneration therapy. This innovative smart product has been certified by the U.S. FDA and China's NMPA and is used as a medical-grade screening and treatment product. The virtual reality device automatically tracks eye movement trajectories, requiring no physical action from the user, and completes the screening in just 5 minutes. It can easily identify risks of mild cognitive impairment (MCI) and dementia with an accuracy rate of 78% - 91%. After the screening, AI automatically analyzes data from six cognitive areas of the user and recommends a tailored list of virtual reality game therapies. During the game therapy, AI analyzes user data and adjusts the difficulty in real-time, customizing it to achieve optimal training results.SMART solution for occupational therapy centers, community rehabilitation centers, and nursing homes.For more information, please contact:(852) 9711 9922

World-First Rapid Test for Early Dementia Risk AD Check認知測™ Rapid utilizes world-leading patented technology to detect Amyloid β-protein fragments in urine—a key biomarker associated with dementia—to assist in screening potential cognitive risks. Designed as a rapid diagnostic kit, the test requires only a small urine sample and delivers results with 10 minutes. This non-invasive, streamlined, and highly efficient workflow makes it an ideal tool for both preliminary screenings and long-term health monitoring. By identifying risk signals early, users can strategically plan targeted medical follow-ups and professional diagnostics, ensuring critical intervention during the " golden intervention period."The technology has earned extensive international recognition, including the CE certification (EU) and medical device registrations across China and Southeast Asia. It holds invention patents in major jurisdictions, including China, Europe, Japan, and Australia. Clinical studies comparing AD Check™ Rapid with Aβ-PET imaging demonstrate high diagnostic performance, with sensitivity and specificity reaching approximately 80% and 90%, respectively

AD Check 認知測™ uses a breakthrough medical technology that has been clinically validated and recognized by the U.S. Food and Drug Administration (FDA) to accurately detect the levels of a biomarker related to Alzheimer’s Disease (AD) pathology in the blood: phosphorylated Tau217 protein (p-Tau217). This helps assess the risk of Alzheimer’s Disease (AD) pathology and allows for regular monitoring of risk changes as individuals age.Research further indicates that the testing technology used in AD Check 認知測™ is consistent with the results of traditional positron emission tomography (PET-Aβ, PET-Tau) and cerebrospinal fluid biomarkers (CSF Aβ42/40, and CSF p-Tau181).AD Check認知測™ accuracy reaches 96%, with a sensitivity of 98.2% and a specificity of 98.6%,test by local accredited laboratory.

Discover Early Risks of Mild Cognitive Impairment (MCI) and Seize Early Treatment Opportunities to Delay Disease ProgressionBDR Technology Overview (Free On-Site Trials Available May 16-18)Electroencephalography (EEG) signals are one of the effective tools for diagnosing brain disorders. The BDR system is FDA approved in the United States and utilizes a 5-minute EEG collection followed by AI analysis to calculate the probabilities of normal and mild brain degeneration, continuously monitoring degenerative trends. This technology offers a non-invasive, convenient, safe screening process with clinical data validation, achieving an accuracy rate of 84%. BDR has successfully overcome the challenges of traditional methods in identifying early brain degeneration, representing an innovative application of medical technology in early screening. [2] Wijaya A, Setiawan NA, Ahmad AH, Zakaria R, Othman Z. Electroencephalography and mild cognitive impairment research: A scoping review and bibliometric analysis (ScoRBA). AIMS Neurosci. 2023 Jun 13;10(2):154-171. doi: 10.3934/Neuroscience.2023012. PMID: 37426780; PMCID: PMC10323261. Achieve Early and Accurate Assessment of Brain Degeneration Risk to Delay and Prevent Ongoing Deterioration!SMART solution for use by medical institutions and elderly care service organizations. For more information, please contact:(852) 9711 9922

Accurate, Objective Depression Risk Assessment,&nbsp;Effectively Assisting&nbsp;Clinical Psychological TreatmentSEA Technology Introduction (Free On-Site Trials Available May 16-18)The SEA system is the world's first system to analyze brainwave stress indices. This system is FDA approved in the US and utilizes a 5-minute collection of brain signals followed by AI analysis. It provides objective data assessment beyond self-perception and behavioral observation, displaying an intuitive stress data distribution chart to assist in discovering latent depression. This technology offers a non-invasive, convenient, safe screening process with clinical data validation, achieving an accuracy rate of 84%. It can assist experts or patients themselves in screening and monitoring conditions for treatment reference, complementing traditional diagnostic methods with meaningful innovative intelligent testing data. SMART solution for use by mental health communities/counseling centers and medical institutions.For more information, please contact:(852) 97119922

Fair at a Glance

Exhibitor List

Product List

Hall Plan

Success Stories

Fair Catalogue 2026

Important Notices

Fair

Apply Booth

Participation Fee & Format

Advertising Opportunities

Resources Centre

Exhibit

eNews

HKTDC Marketplace App & e-Badge

Visitor’s Rules and Regulations

Caution on Third Party Promotional Offers

Visit

Press Releases

Photo Gallery

Video Gallery

Social Media / Digital News

Supporting Media

Media Centre

Press

Events

Visa/Permit for Entering Hong Kong

Visa Application & Travel Arrangements to Chinese Mainland

Hotel Offerings

Airfare Offerings

Dining Offers

Special Offers from Hong Kong Airport Authority

Customs Requirements on Cross-border Cash Controls

Travel to Fairground

Information for Muslim Visitors

Explore Hong Kong

Adverse Weather Arrangements

Travel Info

Enquiries

HKTDC Events

Participation Fee & Format 2027

Visitor Pre-registration

Homepage

Circular

Additional Facilities & Services Order Form

Exhibitors' Manual

Tips for New Exhibitors

Supporting Media 2026

Fair Spotlights

Special Airfares from Cathay Pacific

Fast Track Immigration for Fair Participants

Green Tips

Hygiene Measures & Health Tips

Contact Us

Social Media / Digital News - 2021

Social Media / Digital News - 2019

Social Media / Digital News - 2018

Social Media / Digital News - 2017

Social Media / Digital News - 2016

Virtual Booths

Press Release

Agenda

Intelligence Hub

World of Health and Wellness

World of Health and Wellness - Information

World of Health and Wellness - Contact Us

World of Health and Wellness - At a Glance

World of Health and Wellness - Product Category Listing

Replay Video

Social Media / Digital News - 2022

eBrochure

Airfare offerings

1st Important Circular

Social Media / Digital News - 2024

Welcome Kit